WallStSmart

MediciNova Inc (MNOV)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MediciNova Inc generates 24% more annual revenue ($920,480 vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. MNOV earns a higher WallStSmart Score of 30/100 (F).

MNOV

Avoid

30

out of 100

Grade: F

Growth: 6.3Profit: 2.5Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -7.40

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MNOV3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
240.6%10/10

Revenue surging 240.6% year-over-year

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Price/BookValuation
2.4x8/10

Reasonable price relative to book value

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

MNOV4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$79.74M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
16.9x4/10

Trading at 16.9x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : MNOV

The strongest argument for MNOV centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 240.6% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : MNOV

The primary concerns for MNOV are EPS Growth, Market Cap, Profit Margin.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

MNOV profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

MNOV is growing revenue faster at 240.6% — sustainability is the question.

RVMD generates stronger free cash flow (-745M), providing more financial flexibility.

Bottom Line

MNOV scores higher overall (30/100 vs 24/100) and 240.6% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

MediciNova Inc

HEALTHCARE · BIOTECHNOLOGY · USA

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapies for the treatment of serious diseases with unmet medical needs in the United States. The company is headquartered in La Jolla, California.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?